直接经皮冠状动脉介入治疗术前负荷剂量阿托伐他汀治疗对急性心肌梗死患者近期预后的影响

被引：39

作者：

郑博

王新刚

龚艳君

李建平

陈明

霍勇

洪涛

机构：

[1] 北京大学第一医院心内科

来源：

中国介入心脏病学杂志 | 2013年 / 21卷 / 01期

关键词：

心肌梗死; 阿托伐他汀; 血管成形术,经腔,经皮冠状动脉; 冠状动脉循环;

D O I：

暂无

中图分类号：

R542.22 [];

学科分类号：

1002 ; 100201 ;

摘要：

目的了解直接PCI术前负荷剂量阿托伐他汀治疗对ST段抬高型心肌梗死患者冠脉血流灌注、短期心血管不良事件以及安全性的影响。方法入选2010年1月至2011年3月在北京大学第一医院就诊且既往未服用他汀类药物的ST段抬高型心肌梗死患者83例,根据是否于直接PCI术前应用负荷剂量阿托伐他汀治疗分为强化组(阿托伐他汀80mg,41例)和对照组(无他汀预处理,42例),术后均接受阿托伐他汀20mg,1次/天治疗。主要终点为术后即刻TIMI血流分级、校正的TIMI血流帧数、TIMI心肌灌注分级。次要终点为术后30天的心血管死亡、非致死性心肌梗死和靶血管血运重建的复合终点。安全性终点为出院前肝酶、肌酸激酶以及肾功能水平。结果强化组相比对照组术后即刻TIMI3级血流比例显著增加(87.8%比64.3%,χ2=6.28,P=0.02),校正的TIMI血流帧数明显减低(21.72±9.42比32.64±15.51,t=-3.87,P<0.001),而强化组TIMI心肌灌注分级亦明显高于对照组(2.71±0.64比2.15±0.74,t=3.68,P<0.001)。次要终点中,强化组和对照组分别有4.9%和4.8%出现主要心血管不良事件(χ2=0.001,P=0.926)。出院前两组丙氨酸氨基转移酶、肌酸激酶以及肌酐水平差异无统计学意义。多因素分析显示,在校正年龄、性别、吸烟、糖尿病、血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂、后扩张、血栓抽吸术等因素后,术前应用阿托伐他汀80mg负荷剂量仍为避免出现慢血流/无复流的独立预测因素(OR=0.22,95%CI0.06～0.87,P=0.03)。结论强化阿托伐他汀负荷剂量可以改善ST段抬高型心肌梗死患者直接PCI术后的冠状动脉血流及心肌灌注,并且不增加不良反应的发生率。

引用

页码：41 / 45

页数：5

共 13 条

[1]

Incidence, Predictors and Outcomes of Subacute Stent Thrombosis following Primary Stenting for ST-elevation Myocardial Infarction[J] . Su-Kiat Chua,Huei-Fong Hung,Jun-Jack Cheng,Jen-Hsiang Wang,Huey-Ming Lo,Peiliang Kuan,Shih-Huang Lee,Sheng-Chang Lin,Jer-Young Liou,Che-Ming Chang,Chiung-Zuan Chiu,Kou-Ci Shyu.Journal of the Formosan Medical Association . 2010 (6)

[2] 5-Year Prognostic Value of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction [J].

Ndrepepa, Gjin ;

Tiroch, Klaus ;

Fusaro, Massimiliano ;

Keta, Dritan ;

Seyfarth, Melchior ;

Byrne, Robert A. ;

Pache, Juergen ;

Alger, Patricia ;

Mehilli, Julinda ;

Schoemig, Albert ;

Kastrati, Adnan .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (21) :2383-2389

[3] Effect of Previous Treatment With Statins on Outcome of Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention [J].

Lev, Eli I. ;

Kornowski, Ran ;

Vaknin-Assa, Hana ;

Ben-Dor, Itsik ;

Brosh, David ;

Teplitsky, Igal ;

Fuchs, Shmuel ;

Battler, Alexander ;

Assali, Abid .

AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (02) :165-169

[4]

Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study[J] . Pieter J Vlaar,Tone Svilaas,Iwan C van der Horst,Gilles FH Diercks,Marieke L Fokkema,Bart JGL de Smet,Ad FM van den Heuvel,Rutger L Anthonio,Gillian A Jessurun,Eng-Shiong Tan,Albert JH Suurmeijer,Felix Zijlstra.The Lancet . 2008 (9628)

[5]

Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention[J] . Giuseppe Patti,Vincenzo Pasceri,Giuseppe Colonna,Marco Miglionico,Dionigi Fischetti,Gennaro Sardella,Antonio Montinaro,Germano Di Sciascio.Journal of the American College of Cardiology . 2007 (12)

[6] The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction [J].

Celik, T ;

Kursaklioglu, H ;

Iyisoy, A ;

Kose, S ;

Kilic, S ;

Amasyali, B ;

Kardesoglu, E ;

Isik, E .

CORONARY ARTERY DISEASE, 2005, 16 (05) :321-326

[7] Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography [J].

Hinoi, T ;

Matsuo, S ;

Tadehara, F ;

Tsujiyama, S ;

Yamakido, M .

AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (01) :89-91

[8]

Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study[J] . Vincenzo Pasceri,Giuseppe Patti,Annunziata Nusca,Christian Pristipino,Giuseppe Richichi,Germano Di Sciascio.Circulation . 2004 (6)

[9] Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome [J].

Chang, SM ;

Yazbek, N ;

Lakkis, NM .

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2004, 62 (02) :193-197

[10]

Atorvastatin, administered at the onset of reperfusion, and independent oflipid lowering, protects the myocardiumby up-regulating a pro-survival pathway[J] . Robert M Bell,Derek M Yellon.Journal of the American College of Cardiology . 2003 (3)

← 1 2 →